AKASA

American medicine is the best in the world. But the American healthcare system is challenged by high administrative costs that burden patients, health systems, and insurance companies with unnecessary expenses. We are focused on addressing those challenges.

We use GenAI to improve the most pressing financial pain points in the revenue cycle. We’re one of the first companies to deploy GenAI for practical use cases within healthcare. That gives health systems the ability to focus on what really matters: helping patients.

This is one of the most exciting times to join AKASA. Bookings for our GenAI product suite have increased 10x in the last year. We also recently closed our biggest deal in company history. Our customer base represents more than $120B+ in net patient revenue and includes the most innovative health systems in the country, like Stanford, Johns Hopkins, and Cleveland Clinic. And we’re just getting started!

Some of our most recent recognitions include being named one of the fastest-growing GenAI startups to watch by AIM Research and an “AI Revenue Cycle Leader” by Black Book in 17 out of 18 categories. Our CEO was ranked among the “Top 50 Healthcare Technology CEOs” by the Healthcare Technology Report, and we have been certified as a “Great Place to Work” for the past five years in a row, just to name a few.